HA
HAZ.F Haemonetics Corporation
- Market cap
- EUR 4.87B
- P/E
- 57.2x
- P/B
- 5.91x
- ROE
- 17.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is HAZ.F undervalued?
Graham numberThe Graham number of Haemonetics Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Haemonetics Corporation fundamental analysis
No fundamental analysis for Haemonetics Corporation yet.
Haemonetics Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their dono…
Full company profileHaemonetics Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Haemonetics Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 886M | 904M | 968M | 988M | 870M | 993M | 1.17B | 1.31B | 1.36B | 1.33B | 1.39B |
| Gross Profit | 378M | 412M | 418M | 485M | 398M | 506M | 615M | 692M | 749M | 788M | 847M |
| Operating Income | 39.2M | 56.2M | 83.5M | 154M | 58.0M | 71.7M | 156M | 175M | 201M | 241M | 265M |
| EBITDA | - | 153M | 193M | 214M | 174M | 178M | 249M | 262M | 337M | 268M | 375M |
| Net Income | -26.3M | 45.6M | 55.0M | 76.5M | 79.5M | 43.4M | 115M | 118M | 168M | 97.3M | 159M |
| EPS | -0.50 | 0.87 | 1.08 | 1.52 | 1.56 | 0.85 | 2.29 | 2.31 | 3.48 | 2.09 | 3.48 |
| Balance Sheet | |||||||||||
| Total Assets | 1.24B | 1.24B | 1.27B | 1.27B | 1.82B | 1.86B | 1.93B | 2.20B | 2.45B | 2.40B | 2.41B |
| Total Liabilities | 499M | 485M | 607M | 680M | 1.09B | 1.11B | 1.12B | 1.24B | 1.63B | 1.60B | 1.51B |
| Shareholders' Equity | 740M | 752M | 668M | 587M | 732M | 749M | 818M | 960M | 821M | 796M | 898M |
| Cash & Short-term Investments | 140M | 180M | 169M | 137M | 192M | 259M | 284M | 179M | 307M | 245M | 261M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 160M | 220M | 159M | 158M | 109M | 172M | 273M | 182M | 182M | 293M | 361M |
| Capital Expenditure | 76.1M | 74.8M | 119M | 48.8M | 37.0M | 96.5M | 110M | 38.1M | 39.3M | 32.8M | 45.4M |
| Free Cash Flow | - | 146M | 40.3M | 109M | 71.8M | 75.8M | 163M | 144M | 142M | 260M | 315M |
| Ratios | |||||||||||
| ROE | -3.6% | 6.1% | 8.2% | 13.0% | 10.9% | 5.8% | 14.1% | 12.2% | 20.4% | 12.2% | 17.7% |
| ROA | -2.1% | 3.7% | 4.3% | 6.0% | 4.4% | 2.3% | 6.0% | 5.4% | 6.8% | 4.1% | 6.6% |
| Net Profit Margin | -3.0% | 5.0% | 5.7% | 7.7% | 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% | 11.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Haemonetics Corporation dividends
Haemonetics Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Dec 3, 2012.
Who owns Haemonetics Corporation
- Insiders 1.28%
- Institutions 98.73%
- Public & others 0.00%
- Shares outstanding 45.5M
- Free float 44.9M
Haemonetics Corporation company profile
- Company name
- Haemonetics Corporation
- Ticker
- HAZ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,009
- Fiscal year end
- March
- Address
- 125 Summer Street, Boston, MA, United States, 02110
- Phone
- 781 848 7100
- Website
- haemonetics.com
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics Corporation management
10- Mr. Christopher A. SimonCEO, President & Director · born 1964
- Mr. James C. D'Arecca CPACFO, Executive VP & Financial Officer · born 1971
- Mr. Frank W. Chan Ph.D.Executive VP & COO · born 1970
- Ms. Michelle L. Basil Esq., J.D.Executive VP, General Counsel & Secretary · born 1973
- Mr. Roy GalvinExecutive VP & Chief Commercial Officer · born 1970
- Ms. Farris Maryanne E. MaunsellVP, Chief Accounting Officer & Principal Accounting Officer · born 1976
- Ms. Olga GuyetteVP of IR & Treasury
- Mr. Josh GitelsonSenior Director of Global Communications
- Mr. Rajeev VarmaSenior Vice President of Strategy & Corporate Development
- Ms. Laurie A. MillerSenior VP & Chief Human Resources Officer · born 1974